Top Banner
Anthracycline Side Effects •Myelosuppression , dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia •Nausea & vomiting •Mucositis & diarrhea , common but not dose limitng •Cardiotoxicity •Extravasation •Alopecia
12

Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &

Dec 27, 2015

Download

Documents

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &

Anthracycline Side Effects•Myelosuppression , dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia•Nausea & vomiting•Mucositis & diarrhea , common but not dose limitng•Cardiotoxicity•Extravasation•AlopeciaNausea &vomiting:↑↑↑↑Mitoxantrone (70% of the patients)↑↑↑Doxorubicin (50% of the patients)↑↑Daunorubicin , Idarubicin , Epirubicin↑Doxil® (liposomal Doxorubicine) (20% of the patients)

Page 2: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &

Special side effectsDoxorubicinDaunorubicinIdarubicinEpirubicinDoxil®

Hyperpigmentation of nails , rarely skin rash & urticaria.Red orange discoloration of urine.

Doxil® HAND FOOT SYNDROME

Mitoxantrone Blue discolourationof fingernails,sclera & urine 1-2 days after treatment

Valrubicin Blood in urineIncontinencepainful or difficult urinationUnusually frequent urination

Page 3: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &

Extravasation•Extravasation injury usually refers to the damage caused by leakage of solutions from the vein to the surrounding tissue spaces during intravenous administration.

•Once an extravasation has occurred, damage can continue for months and involve nerves, tendons and joints.

•If treatment is delayed, surgical intervension, skin grafting, and even amputation may be the unfortunate consequences

Page 4: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &
Page 5: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &
Page 6: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &

Doxorubicin extravasation

Necrosis & tissue ulceration may occur some time after the extravasation has occurred, e.g. Daunorubicin extravasation

Page 7: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &
Page 8: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &
Page 9: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &

Extravasation control•Doxorubicin•Daunorubicin •Mitozantrone •Epirubicin

Apply topical DMSO, every 2 hours at the extravasation site followed by topical hydrocortisone cream and a cold compress.Avoid contact with good skin. If blistering occurs, stop the DMSO and seek further advice. Sodium bicarbonate may have a roleSurgical excision is sometimes required to prevent serious damage

•Doxorubicin Liposomal •Daunorubicin Liposomal

Apply topical hydrocortisone and cover the area with an ice pack for up to 12 hours, then at 8-12 hours post incidence apply DMSO 2 hourly for the next 24 hours.

Page 10: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &

•Some reports of prevention/decreased ulcer formation were obtained when DMSO was used in conjunction with Vitamin E.

•There is one series of patients reported in whom topical application of 99% DMSO was thought to have prevented ulceration.

Page 11: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &

•Venipuncture and placement of the cannula (or other IV access) should be performed by experienced personnel, where available. •(e.g. patients with hardly visible veins, very obese patients, very elderly patients, young children, etc.). •In all other patients, avoid multiple venipunctures in the same area.

•Venipuncture and placement of the cannula (or other IV access) should be performed by experienced personnel, where available. •(e.g. patients with hardly visible veins, very obese patients, very elderly patients, young children, etc.). •In all other patients, avoid multiple venipunctures in the same area.

Choose a large, intact vein with good blood flow for the venipuncture and placement of the cannula. Choose a large, intact vein with good blood flow for the venipuncture and placement of the cannula.

Prevention of Extravasation in hospitals

Prevention of Extravasation in hospitals

Page 12: Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &

The IV infusion should be freely flowing. The arm with the infusion should not begin to swell (oedema), "get red" (erythema), "get hot" (local temperature increase), and the patient should not notice any irritation or pain on the arm. If this occurs, stop infusion immediately!

The IV infusion should be freely flowing. The arm with the infusion should not begin to swell (oedema), "get red" (erythema), "get hot" (local temperature increase), and the patient should not notice any irritation or pain on the arm. If this occurs, stop infusion immediately!

The infusion should consist of a suitable carrier solution with an appropriately diluted medicinal/chemotherapy drug inside.

The infusion should consist of a suitable carrier solution with an appropriately diluted medicinal/chemotherapy drug inside.

After the IV infusion has finished, flush the vein "clean" with only the carrier solution. After the IV infusion has finished, flush the vein "clean" with only the carrier solution.